AGC and Neusignal Therapeutics Collaborate to Advance NTX-083, an Oral Alzheimer's Disease Candidate, Toward U.S. Clinical Trials
核心洞察
AGC Inc. (搜索) provided end-to-end CDMO support for the drug substance of NTX-083, an Alzheimer's disease (搜索) candidate developed by Neusignal Therapeutics, covering process development, GMP manufacturing, and regulatory support.
AGC completed the CMC documentation required for a U.S. IND application, positioning NTX-083 to enter clinical trials in the United States in 2026.
NTX-083 is a novel small-molecule oral drug candidate with a new mechanism of action expected to improve cognitive and psychiatric symptoms while offering disease-modifying potential.
AGC Inc. (搜索) (Headquarters: Tokyo; President: Yoshinori Hirai) has highlighted its end-to-end support capabilities as a small-molecule pharmaceutical CDMO through a collaboration with Neusignal Therapeutics, Inc. (搜索) (Headquarters: Tokyo; CEO: Itaru Arimoto), focused on advancing NTX-083, an Alzheimer's disease (搜索) drug candidate. Under the collaboration, AGC provided integrated support for the drug substance of NTX-083, covering process development, GMP manufacturing, and regulatory support from the early stages of development. In addition to establishing the manufacturing process for the drug substance, AGC completed the preparation of documentation required for an Investigational New Drug (IND) application in the United States. NTX-083 is scheduled to enter clinical trials in the United States in 2026.
A Novel Oral Candidate for Alzheimer's Disease
Alzheimer's disease (搜索) is one of the disorders with significant unmet medical needs, and the number of patients continues to increase worldwide. Neusignal Therapeutics is advancing the development of NTX-083 with the goal of providing a new treatment option for patients facing this challenge. NTX-083 is a novel small-molecule oral drug candidate with a new mechanism of action that is expected to improve cognitive and psychiatric symptoms while also offering disease-modifying potential.
Neusignal Therapeutics, Inc. (搜索) is a drug discovery startup originating from Tohoku University that focuses on the research and development of treatments for central nervous system disorders, including Alzheimer's disease (搜索). In 2026, the company raised a total of ¥5.32 billion in its Series B financing round, including support from AMED's Strengthening Program for Pharmaceutical Startup Ecosystem. The company is currently preparing to initiate a Phase 1b clinical trial in patients with Alzheimer's disease in the United States.
Integrated CDMO Support from Development to Clinical Stage
In the process development and manufacturing of the NTX-083 drug substance, AGC supported a smooth transition from the early stages of development to the clinical stage through collaboration between its Yokohama Technical Center, a process development site, and its Chiba Site, a GMP manufacturing site. AGC also supported the preparation of CMC (Chemistry, Manufacturing and Controls)-related documentation required for the IND application.
AGC's Commitment to Well-being
Under its medium-term management plan, AGC plus-2026, the AGC Group has identified three social values it aims to create through its products and technologies. One of these values, "Well-being," aims to contribute to safe, secure, and healthy lives through the stable supply of products and services essential to healthcare and everyday life. Through its pharmaceutical and agrochemical CDMO services, the Life Science business supports drug discovery and pharmaceutical development and contributes to improving people's health and quality of life.